| abstract |
Methods and compositions are provided for the treatment of immune disorders such as autoimmune diseases or cancer with combination therapy with agents that inhibit the development or maintenance of Th17 cells. A treatment regimen is provided in which an antagonist of pro-inflammatory cytokines is administered for a time sufficient to relieve signs and symptoms of acute phase recurrence of autoimmune disease or cancer, and treatment with antagonists of IL-23 is an acute event Continue for longer to prevent recurrence. PGE2 and CD161 antagonists are also disclosed for use in the treatment of autoimmune, inflammatory and proliferative disorders. |